Reports Q4 revenue $58.5M, consensus $53.58M; $302M of cash and cash equivalents and investments at December 31, 2023. “We doubled our total revenues to nearly $200 million in 2023 and ended the year with a robust fourth quarter total revenue of $58 million,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “With our strong year-end cash position of over $300 million, we are well positioned to capitalize on upcoming data read-outs for Afrezza and move MNKD-101 (clofazimine inhalation suspension) into phase 3 and MNKD-201 (nintedanib DPI) into phase 1 in the first half of 2024.” Fourth Quarter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MNKD:
- Is MNKD a Buy, Before Earnings?
- MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
- MannKind says INHALE-1 study now fully enrolled
- MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
- MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
